NCT02912533已完成3 期
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 主要终点
- Measure adverse events
研究概览
简要总结
The purpose of this study is to investigate the safety and efficacy for 52-week dosing of JR-131 in renal anemia patients with chronic kidney disease (CKD).
研究设计
- 研究类型
- Interventional
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients being treated with erythropoiesis stimulating agent.
排除标准
- •Patients having complication or history of a cardiovascular / lung / brain infarction.
- •Patients having a pronounced hemorrhagic lesion.
研究组 & 干预措施
JR-131
Experimental
干预措施: JR-131 (Drug)
结局指标
主要结局
Measure adverse events
时间窗: 52 weeks
次要结局
- Hemoglobin level(52 weeks)
研究者
相似试验
已完成
3 期
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)AnemiaNCT02912494Kissei Pharmaceutical Co., Ltd.
已完成
2 期
An Early Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Anemia Correction study>Anemia with CKDJPRN-jRCT2080222207Japan Tobacco Inc.40
已完成
3 期
A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.Anemia of Chronic Kidney DiseaseNCT04027517JW Pharmaceutical172
已完成
3 期
A Long-Term Study of JNS007ER in Patients With SchizophreniaSchizophreniaNCT01561898Janssen Pharmaceutical K.K.228
已完成
2 期
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's DiseaseAlzheimer's DiseaseNCT02260674Janssen Research & Development, LLC114